

Prof. Peter O’Gorman MD, PhD

BCNI Principal Investigator

Name: Professor Peter O’Gorman, MD PhD FRCPath
FRCPI

Current Position: Director of Pathology/Consultant
Haematologist,
UCD Clinical Professor
UCD School of Medicine
Mater University Hospital, Dublin, Ireland

Contact: pogorman@mirtireland.com



Background Career Information:

Prof. O’Gorman took up a Clinical Haematologist post in 2003 at the Mater University Hospital and has developed clinical services there. A new 30 bed state of the art clinical Haematology/Oncology facility was officially opened in 2015 by Prof. James Watson, Cold Spring Harbour, New York, USA. There are now 7 Haematologist on the Mater Campus. Over the last five years, Prof. O’Gorman has been Director of the Pathology Laboratories. As part of this role he has been Director of the New Next Generation Sequencing facility that officially opened in September 2017. This will open a new era of Precision Medicine in Ireland where state of the art DNA sequencing technology will identify a key driver mutations that will direct clinical interventions by the physician or surgeon.

Prof. O’Gorman was national lead for Blood Cancer Trials with Clinical Trials Ireland from 2010 – 2014. This culminated in the development of the RVD SC phase II Trial in newly diagnosed Multiple Myeloma. This was a partnership with the Dana Farber Cancer Institute lead by Prof. Paul Richardson and Prof. Peter O’Gorman. Further trials using this model are under development. Prof. O’Gorman is also one of five national Principle Investigators as part of the Irish Cancer Society/Science Foundation of Ireland, funded Blood Cancer Network Ireland. This network will focus specifically on Phase I Trials and is already active in its first year.

Prof. O’Gorman’s scientific focus is on the development of predictive biomarkers and the identification of novel targets for drug development using proteogenomic techniques.

Prof. O’Gorman has developed an important strategic educational linkage with the Dana Farber Cancer Institute and Harvard Medical School in Boston, USA. In 2007 he developed an MD-PhD mentorship program with Prof. Ken Anderson and Prof. Martin Clynes. So far eight PhD students have progressed through this program. The goal is to develop a new generation of Clinical/Scientists that will drive translational myeloma research into the future.